October 28th 2023, 5:00pm
Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.
October 27th 2023, 9:00pm
Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.
October 27th 2023, 1:00pm
The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.
October 25th 2023, 10:00pm
The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
October 25th 2023, 3:00pm
Patients with HR-positive, HER2-negative high-risk early breast cancer tended to experience improved invasive disease and distant relapse-free survival after adding Verzenio to endocrine therapy.
October 24th 2023, 11:00pm
Patients with previously treated advanced neuroendocrine tumors who received treatment with Cabometyx had improved progression-free survival compared with placebo.
October 24th 2023, 3:00pm
Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.
October 24th 2023, 1:00pm
Central nervous system progression-free survival was shown to improve with Enhertu than with alternative treatments for patients with HER2-positive metastatic breast cancer and brain metastases.
October 23rd 2023, 10:00pm
Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.
October 23rd 2023, 9:00pm
Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.
FDA Approves Imdelltra For Advanced SCLC
Erleada, ADT ‘One-Two Punch’ in Prostate Cancer Treatment
My ‘Bag of Tricks’ Helps Overcome Fear During Stage 4 Ovarian Cancer
Adding Tecentriq to Chemo Did Not Boost TNBC Survival